Loading clinical trials...
Loading clinical trials...
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High-Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Conditions
Interventions
ADSTILADRIN
Locations
34
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Keck School of Medicine at USC Medical Center
Los Angeles, California, United States
The Urology Center of Colorado
Denver, Colorado, United States
University of Florida - UF Health Davis Center Pavilion and Shands Med Plaza
Gainesville, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Start Date
September 19, 2016
Primary Completion Date
May 24, 2019
Completion Date
May 24, 2023
Last Updated
July 29, 2024
NCT05084586
NCT00595088
NCT00322699
Lead Sponsor
Ferring Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions